graph Evidence gap map comparisons
ipilimumab based treatmentatezolizumab based treatmentdurvalumab based treatmentpembrolizumab based treatmentdurvalumab plus tremelimumab
ipilimumab plus SoC atezolizumab plus SoC durvalumab plus etoposide and platin pembrolizumab plus SoC durvalumab plus tremelimumab plus SoC
Extensive stage SCLC (Es-SCLC) - 1st Line (L1) 5           
Comparator:  vs placebo plus SoC;   vs etoposide plus platin; 
Risk of bias:  low;   some concerns;   high;  NA;